FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2011106585> ?p ?o ?g. }

• W2011106585 abstract "Ras homolog gene family, member A (RhoA) is a small GTPase that plays critical roles in several essential cell functions, such as migration, adhesion, proliferation, and gene expression. 1 RhoA switches between a GTP-bound active form and a GDP-bound inactive form. The activated RhoA directly interacts with its downstream effectors, such as Rho kinase (ROCK) to regulate actomyosin dynamics, or mDia1 to control stress fiber and filopodia formation. The activity of RhoA is primarily regulated by guanine nucleotide exchange factors (GEFs), GTPase-activating protein (GAP), and guanine nucleotide-dissociation inhibitors (GDIs). RhoA was initially postulated as an oncogene in 1989. 2 Even though the amplification of RhoA was capable of transforming mouse fibroblasts, point mutations at codon 14 and 64 were not tumorigenic in the same model. 2 Previous cancer genome sequencing analysis also failed to identify RhoA mutations in most common human cancers, and consequently, it was not thought to be altered by somatic mutation in human cancers. In February of 2014, a recurrent mutation of RhoA (G17V) was reported to be present in 67% of angioimmunoblastic T cell lymphoma (AITL) and 18% of peripheral T cell lymphoma (PTCL), but not otherwise specified (PTCL-NOS) samples. 3 This finding was quickly validated by two other groups.4, 5 In addition, RhoA mutations were found in pediatric Burkitt lymphoma treated according to the NHL-BFM protocols. 6 However, RhoA mutation is not limited to a subset of lymphoma, as three large studies published this year have indicated that RhoA is mutated in 14% of diffuse-type gastric carcinoma samples but not in intestinal type tumors.7, 8, 9 Therefore, RhoA is quickly emerging as a somatic mutational target in these tumor types. The first interesting aspect of this emerging story is that RhoA mutations are limited to these specific tumor types, which suggests that the function of RhoA may be cell type-specific. It is known that the expression of many RhoA regulators is tissue or cell type-specific, and recent mouse model studies have indicated that the regulation of these downstream signaling pathways by RhoA is also cell type-specific. 10 Consequently, the biological significance of RhoA activity will vary among different cell types, and it will be important to determine in the future the biological effect of RhoA depletion in these cell types in mouse models. The type of recurrent RhoA mutations observed in these tumors is another topic of interest. In AITL and PTCL, the dominant mutation observed is G17V, which resides in the GTP/GDP binding site. G17V-mutant RhoA does not interact with its effector molecule rhotekin and suppresses F-actin stress fiber formation. 3 In addition, G17V-mutant RhoA appears to act in a dominant-negative capacity to promote cell proliferation and invasion. 4 The mutational hotspots of RhoA in diffuse-type gastric carcinoma are Y42C, R5Q/W, L57V and G17E. Y42C resides at the C-terminal edge of the core effector binding region of RhoA, and a previous study suggested that this mutation only attenuates the activation of protein kinase N but does not abrogate the activation of mDia or ROCK1. 8 A Rho binding domain assay also suggested that Y42C and L57V mutants have attenuated abilities to associate with GTP. 9 Together, these studies suggest that wild-type RhoA has tumor suppressor functions, while mutated RhoA inhibits wild-type function through a dominant negative mechanism. However, if RhoA is truly a tumor suppressor, one would expect this gene to be frequently inactivated by other gene inactivation mechanisms, such as nonsense or frame-shift mutations in these tumor types. The recurrent nature of RhoA mutations in AITL, PTCL and diffuse-type gastric carcinoma strongly suggests that these hotspot mutations result in a gain-of-function alteration in an unidentified signaling pathway; nevertheless, in the absence of any supporting data, the question still remains whether RhoA is an oncogene or tumor suppressor gene. From the cancer treatment perspective, the recurrent mutational hotspots of this protein represent ideal targets for small molecule inhibitors as therapeutic reagents. If the RhoA mutants act in a dominant negative fashion, such molecules could disrupt their interaction with the wild-type protein to restore RhoA function. On the other hand, if RhoA mutants are oncogenes, the suppression of their activities by these molecules should inhibit tumorigenesis. In either case, the future development of these therapeutic reagents holds promise for cancer patients with RhoA mutations." @default.
• W2011106585 created "2016-06-24" @default.
• W2011106585 creator A5052926415 @default.
• W2011106585 creator A5064924657 @default.
• W2011106585 creator A5069603616 @default.
• W2011106585 date "2015-03-01" @default.
• W2011106585 modified "2023-09-27" @default.
• W2011106585 title "RhoA, a novel tumor suppressor or oncogene as a therapeutic target?" @default.
• W2011106585 cites W1627528893 @default.
• W2011106585 cites W1965619419 @default.
• W2011106585 cites W1989261348 @default.
• W2011106585 cites W2007490905 @default.
• W2011106585 cites W2069271377 @default.
• W2011106585 cites W2075256713 @default.
• W2011106585 cites W2102312968 @default.
• W2011106585 cites W2115638428 @default.
• W2011106585 cites W4233431843 @default.
• W2011106585 doi "https://doi.org/10.1016/j.gendis.2014.10.001" @default.
• W2011106585 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4477828" @default.
• W2011106585 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26114154" @default.
• W2011106585 hasPublicationYear "2015" @default.
• W2011106585 type Work @default.
• W2011106585 sameAs 2011106585 @default.
• W2011106585 citedByCount "5" @default.
• W2011106585 countsByYear W20111065852016 @default.
• W2011106585 countsByYear W20111065852019 @default.
• W2011106585 countsByYear W20111065852022 @default.
• W2011106585 crossrefType "journal-article" @default.
• W2011106585 hasAuthorship W2011106585A5052926415 @default.
• W2011106585 hasAuthorship W2011106585A5064924657 @default.
• W2011106585 hasAuthorship W2011106585A5069603616 @default.
• W2011106585 hasBestOaLocation W20111065851 @default.
• W2011106585 hasConcept C104317684 @default.
• W2011106585 hasConcept C126619667 @default.
• W2011106585 hasConcept C153911025 @default.
• W2011106585 hasConcept C185592680 @default.
• W2011106585 hasConcept C203014093 @default.
• W2011106585 hasConcept C207332259 @default.
• W2011106585 hasConcept C2777093181 @default.
• W2011106585 hasConcept C2779338263 @default.
• W2011106585 hasConcept C2780040266 @default.
• W2011106585 hasConcept C2780298669 @default.
• W2011106585 hasConcept C2781018059 @default.
• W2011106585 hasConcept C29537977 @default.
• W2011106585 hasConcept C502942594 @default.
• W2011106585 hasConcept C54355233 @default.
• W2011106585 hasConcept C62478195 @default.
• W2011106585 hasConcept C86803240 @default.
• W2011106585 hasConcept C95444343 @default.
• W2011106585 hasConceptScore W2011106585C104317684 @default.
• W2011106585 hasConceptScore W2011106585C126619667 @default.
• W2011106585 hasConceptScore W2011106585C153911025 @default.
• W2011106585 hasConceptScore W2011106585C185592680 @default.
• W2011106585 hasConceptScore W2011106585C203014093 @default.
• W2011106585 hasConceptScore W2011106585C207332259 @default.
• W2011106585 hasConceptScore W2011106585C2777093181 @default.
• W2011106585 hasConceptScore W2011106585C2779338263 @default.
• W2011106585 hasConceptScore W2011106585C2780040266 @default.
• W2011106585 hasConceptScore W2011106585C2780298669 @default.
• W2011106585 hasConceptScore W2011106585C2781018059 @default.
• W2011106585 hasConceptScore W2011106585C29537977 @default.
• W2011106585 hasConceptScore W2011106585C502942594 @default.
• W2011106585 hasConceptScore W2011106585C54355233 @default.
• W2011106585 hasConceptScore W2011106585C62478195 @default.
• W2011106585 hasConceptScore W2011106585C86803240 @default.
• W2011106585 hasConceptScore W2011106585C95444343 @default.
• W2011106585 hasLocation W20111065851 @default.
• W2011106585 hasLocation W20111065852 @default.
• W2011106585 hasLocation W20111065853 @default.
• W2011106585 hasLocation W20111065854 @default.
• W2011106585 hasOpenAccess W2011106585 @default.
• W2011106585 hasPrimaryLocation W20111065851 @default.
• W2011106585 hasRelatedWork W1427537304 @default.
• W2011106585 hasRelatedWork W1516775823 @default.
• W2011106585 hasRelatedWork W190493228 @default.
• W2011106585 hasRelatedWork W1941505138 @default.
• W2011106585 hasRelatedWork W1966034310 @default.
• W2011106585 hasRelatedWork W1967828043 @default.
• W2011106585 hasRelatedWork W1986492134 @default.
• W2011106585 hasRelatedWork W1994756548 @default.
• W2011106585 hasRelatedWork W2042924994 @default.
• W2011106585 hasRelatedWork W2082202504 @default.
• W2011106585 hasRelatedWork W2116719283 @default.
• W2011106585 hasRelatedWork W2126170617 @default.
• W2011106585 hasRelatedWork W2152148281 @default.
• W2011106585 hasRelatedWork W2527047011 @default.
• W2011106585 hasRelatedWork W2557950677 @default.
• W2011106585 hasRelatedWork W2899961405 @default.
• W2011106585 hasRelatedWork W2943522872 @default.
• W2011106585 hasRelatedWork W2990866090 @default.
• W2011106585 hasRelatedWork W3081158222 @default.
• W2011106585 hasRelatedWork W3109044687 @default.
• W2011106585 isParatext "false" @default.
• W2011106585 isRetracted "false" @default.
• W2011106585 magId "2011106585" @default.
• W2011106585 workType "article" @default.